- $1.46bn
- $1.28bn
- $2.80m
Brief: Absci Corp Files For Mixed Shelf Size Not Disclosed - SEC Filing
Absci Q3 revenue misses estimates, net loss widens on R&D spends
Focus: Beyond the Scale: Men turn to cosmetic clinics to complete weight-loss transformation
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Absci falls after Q2 revenue misses estimates
Absci Corp reports results for the quarter ended June 30 - Earnings Summary
Absci Q2 revenue falls and misses analyst expectations
Brief: Absci Q2 Operating Income USD -34.158 Million
Absci Corp expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Broadcom, Micron, Qualcomm
U.S. STOCKS ON THE MOVE-Broadcom, Chemours, Qualcomm
U.S. STOCKS ON THE MOVE-FuelCell, Deep Fission, InMode
U.S. STOCKS ON THE MOVE-Take-Two, Wendy's, Absci
Absci rises on positive hair-loss drug data
Brief: Absci Announces Positive Interim Phase 1 Data From The Headline™ Trial Of Abs-201, A Novel Antibody Targeting The Prolactin Receptor (Prlr)
Absci Q1 revenue drops, misses estimates
Brief: Absci Q1 Pretax Profit USD -29.581 Million
Absci rises as brokerage highlights growing opportunity in hair‑loss market